Abstract：
The 2022 revision of the Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for surgical treatment of breast cancer was updated following a systematic review of the literature using the Medical Information Network Distribution Service (MINDS) procedure, which focuses on the balance of benefits and harms for various clinical questions (CQs). Experts in surgery designated by the JBCS addressed five areas: breast surgery, axillary surgery, breast reconstruction, surgical treatment for recurrent and metastatic breast cancer, and other related topics. The revision of the guidelines encompassed 4 CQs, 7 background questions (BQs), and 14 future research questions (FRQs). A significant revision in the 2022 edition pertained to axillary management after neoadjuvant chemotherapy in CQ2. The primary aim of the 2022 JBCS Clinical Practice Guidelines is to provide evidence-based recommendations to empower patients and healthcare professionals in making informed decisions regarding surgical treatment for breast cancer.
摘要：
在使用医疗信息网络分发服务（MINDS）程序对文献进行系统回顾后，对2022年修订的日本乳腺癌协会（JBCS）的乳腺癌手术治疗临床实践指南进行了更新。它侧重于各种临床问题（CQs）的利弊平衡。JBCS指定的手术专家涉及五个领域：乳房手术，腋窝手术,乳房重建,复发性和转移性乳腺癌的手术治疗，和其他相关主题。指南的修订包括4个CQ，7个背景问题（BQs），和14个未来研究问题(FRQs)。2022年版的重大修订涉及CQ2新辅助化疗后的腋窝管理。2022年JBCS临床实践指南的主要目标是提供循证建议，使患者和医疗保健专业人员能够就乳腺癌的手术治疗做出明智的决定。
